Hand and Finger Arthritis Embolization in Manhattan, NYC

Quick Answer

Hand and finger arthritis embolization briefly slows blood flow in small abnormal vessels around painful arthritic joints, through a tiny puncture at the wrist. Five small uncontrolled studies (204 patients in total) report less pain, but no randomized or sham-controlled trial exists, so it is an early-stage option considered only after standard care has not helped.

When the joints of your fingers or the base of your thumb hurt every day, small tasks get hard. Opening a jar, turning a key, buttoning a shirt, holding a pen. Splints, creams, pills and injections help many people. Some still hurt after trying them and start asking what else exists.

Hand and finger arthritis embolization is one of the newest answers to that question, and one of the least proven. This page explains what it is, what the five published studies found, who was treated and who was kept out, what the procedure involved, and what is still unknown. David Fox, MD, FACS, RPVI, a board-certified vascular surgeon in Manhattan, evaluates patients for hand and finger embolization. We will be blunt about the evidence.

Hand osteoarthritis in brief

Osteoarthritis is the wear-related form of arthritis. The CDC estimates that about 33 million U.S. adults have it, and the hands are one of the places it shows up most often. In the Johnston County Osteoarthritis Project, a study of 2,218 adults aged 45 and older, the estimated lifetime risk of hand osteoarthritis with symptoms was 39.8%. It was higher in women (47.2%) than in men (24.6%).

According to the Arthritis Foundation, three areas are affected most:

The base of the thumb, where the thumb meets the wrist.
The joint closest to the fingertip. Bony lumps here are called Heberden's nodes.
The middle joint of a finger. Bony lumps here are called Bouchard's nodes.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases describes the typical pattern: pain with use that may ease with rest, stiffness that usually lasts less than 30 minutes in the morning or after resting, and joints that slowly enlarge or change shape.

Osteoarthritis is not the same as rheumatoid arthritis, an autoimmune disease that usually affects the same joints on both sides of the body. That matters here, because the embolization studies enrolled people with osteoarthritis only. Our guide to hand osteoarthritis causes, symptoms and diagnosis covers this in more depth.

What hand embolization is and how it is thought to work

Embolization means slowing blood flow through chosen small vessels from inside the artery. In medical journals the hand version is called transarterial embolization (TAE) or transarterial micro-embolization (TAME).

In the published hand studies, a doctor placed a very fine needle or a thin catheter in the artery at the wrist, after numbing the skin in the two studies that describe anesthesia, and slowly infused a short-acting embolic agent. That agent briefly slows flow through the small abnormal vessels around the painful joints.

The reasoning comes from laboratory research on arthritic joints in general, most of it on knee tissue. That work found that inflamed joint lining grows extra small blood vessels, and that sensory nerves grow along those new vessels. Researchers have proposed that these vessels and nerves help keep pain going. One hand study described the target as a "blush" of extra vessels on the X-ray dye picture and saw fewer of them at the second session.

Please read the mechanism as a hypothesis. No study has shown that closing these vessels changes the nerves or the course of hand arthritis. Embolization does not rebuild cartilage. A U.S. embolization registry says plainly that the procedure "does not treat the underlying cartilage destruction."

The same idea has been studied far more in the knee (see genicular artery embolization). Our embolization guide shows how the hand fits beside the knee, heel, shoulder, elbow and hip.

What the studies show so far

As of October 2026, five clinical studies of embolization for hand osteoarthritis have been published, with 204 patients in total. Every one is a single-group, uncontrolled case series. Everyone got the treatment, and nobody was compared with a placebo procedure or another treatment.

Thumb base, Japan, 2021 (31 patients)

A prospective, uncontrolled series from Tokyo treated 31 people with thumb-base arthritis that had not improved after at least three months of standard care. Average pain on a 0 to 10 scale went from 7.2 before treatment to 3.1 at 2 months, 2.8 at 6 months and 2.5 at 24 months. Patients rated themselves improved in 84%, 81% and 77% of cases at 2, 6 and 24 months. No major adverse events were reported. This is the longest follow-up in the hand.

Finger joints, Taiwan, 2023 (58 patients)

A retrospective, uncontrolled series from Taiwan treated 58 people with finger joint arthritis. Average pain went from 6.0 to 2.8 at 1 month, 2.2 at 3 months and 2.4 at 6 months. Only 30 patients were followed to 12 months and only 6 to 18 months. The share who rated the treatment a success was 62.1% at 1 month, 77.6% at 3 months, 70.7% at 6 months, 63.4% at 12 months and 50.0% at 18 months. No severe or life-threatening adverse events were reported.

Finger joints, Japan, 2023 (92 patients)

The largest hand study is a retrospective, uncontrolled series of 92 patients from clinics in Tokyo, Osaka and Kobe. Two procedures were planned for each patient, one to two months apart. At 12 months, 77% had a pain drop of at least 2 points on the 0 to 10 scale. Average pain went from 7.8 to 3.8 at 3 months and 4.0 at 12 months. Pain was reduced, not removed, and about 1 in 4 patients did not meet the study's definition of success. No major adverse events were observed.

Mixed hand joints, Taiwan, 2024 (9 patients)

A small retrospective pilot series treated 9 patients, each with two sessions a month apart. Average pain on a 0 to 100 scale went from 76 to 34 at 1 week and 18 at 6 months, and 8 of 9 patients had at least a 50% drop in pain at 6 months. But pain partly came back at 1 month in 4 of the 9 patients. Hand function scores were not significantly better at 3 and 6 months, and stiffness did not change significantly at any point.

Thumb base, United States, 2026 (14 patients)

The only U.S. study is a prospective, uncontrolled series of 14 patients from a single private clinic in North Carolina. Average pain went from 8.0 to 3.1 at 1 month and 2.6 at 6 months, and 11 of 14 patients (79%) had at least a 50% improvement by the end of the study. No major adverse outcomes were reported. The summary of the paper does not name the embolic agent used.

What is missing

No randomized trial, no sham-controlled trial and no study comparing embolization with splints, injections or surgery has been published for the hand. Without a comparison group, nobody can separate the effect of the procedure from placebo response, from the natural ups and downs of arthritis, or from other treatments patients kept using. The authors of the 9-patient study say so themselves. In the knee, where sham-controlled trials have been done, reviewers describe the results as mixed.

A 2026 independent review placed finger joint and thumb-base embolization in its "hypothesis-generating" category and described the durability as unknown. The American College of Rheumatology and European hand osteoarthritis guidelines do not mention embolization. For the full detail, read what the hand embolization studies show.

Who may be a candidate, and who should not have it

The clearest guide is who the researchers chose to treat. Across the studies, patients generally had:

Osteoarthritis of the finger joints or thumb base, confirmed by a doctor and, in the studies that describe it, by X-ray or formal diagnostic criteria.
Moderate to severe pain. One study required a pain score of at least 4 out of 10 and another required more than 50 out of 100.
Pain that had not improved with standard care such as splints, therapy, anti-inflammatory medicine or injections. Two studies required at least three months of it.

The studies also kept certain people out. These are exclusion criteria from two research protocols, not formal contraindications, but they are the best published guide to who may not be a candidate:

Rheumatoid arthritis, psoriatic arthritis, crystal arthritis or another inflammatory arthritis.
Raynaud's syndrome, scleroderma or other conditions that affect blood flow to the fingers.
Narrowed or blocked arteries in the arm, advanced artery disease, inflammation of the arteries, or a previous clot or tear in the wrist artery.
Allergy to X-ray contrast dye or to the antibiotic used as the embolic agent.
An infection in the area.
Severe kidney disease, pregnancy or breastfeeding.

Raynaud's and scleroderma appear only as trial exclusions. No study reports how such patients do. The same is true for erosive hand osteoarthritis, an aggressive form that no embolization study reports as a separate group.

On allergy: imipenem/cilastatin, the agent used in nearly all the hand studies, is a beta-lactam antibiotic. Its FDA label lists allergy to its components as a reason not to give it and warns of serious allergic reactions with this drug family. Tell your doctor about any antibiotic reaction you have had.

If your joints became hot, red and swollen quickly, or the same joints are swollen on both hands, see your primary doctor or a rheumatologist first. That pattern can point to something other than ordinary osteoarthritis. Our candidate guide walks through all of this step by step.

Questions about your treatment options? Dr. Fox can help.

Book a Consultation

This article is part of our Embolization Guide.

How it compares with standard care

Embolization has not been tested against any standard treatment for the hand, so nobody can say it works better or worse than the options below.

Option	Where it stands
Anti-inflammatory gels and pills	Strongly recommended for hand osteoarthritis in the American College of Rheumatology's 2026 guideline summary.
Splints, hand exercise, occupational therapy	Splints for the thumb base and finger joints and hand exercise are conditionally recommended in the 2026 summary, which also advises referral to occupational therapy when hand use is limited.
Steroid injection into the joint	Conditionally recommended in the 2026 summary. The American Academy of Orthopaedic Surgeons (AAOS) says relief can last weeks to months and that injections can be repeated only a limited number of times.
Surgery	Joint fusion or replacement for fingers, and removal of a small wrist bone or fusion for the thumb base. AAOS describes a cast or splint for 4 to 8 weeks after thumb surgery and several months to full recovery.
Embolization	Five small uncontrolled series, 204 patients. Not mentioned in the American or European hand osteoarthritis guidelines. No head-to-head comparison.

For most people the right order is standard care first. See hand arthritis treatment without surgery for the full list, and hand embolization vs. injections and surgery for a closer comparison. If your pain is at the base of the thumb, our page on thumb arthritis embolization is the most relevant.

What the procedure and recovery were like in the studies

What follows describes the published reports. Dr. Fox will explain his own approach at your visit.

Anesthesia. Local numbing at the wrist in the two studies that describe it. The other reports do not say what was used.
Access. In three of the Asian studies a 24-gauge needle or cannula was placed in a wrist artery; the fourth describes wrist artery access without further detail. The U.S. study used a microcatheter in the radial artery.
Time. A needle-only technique in the 31-patient Japanese study averaged 2.9 minutes. In the 9-patient study, which included dye pictures of the arteries, the average was 15.7 minutes, with a range of 11 to 20.
Afterward. In the 9-patient study, the needle was removed, pressure was held, a band-aid was applied, and patients went home after 20 minutes of observation.
Number of sessions. The 92-patient study planned two procedures one to two months apart. The 9-patient study gave every patient two sessions a month apart.

Relief did not follow a straight line. In the 9-patient study, overall pain was down 55% and night pain down 62% within the first week. Then, at one month, pain had partly returned in 4 of the 9 patients, though it was milder than before treatment. After the second session, 1 of 9 still had returning pain at 3 and 6 months. The authors suspect the treated vessels partly reopen and suggest a two-session plan.

None of the hand studies report time off work, activity limits, splint use afterward, or when patients returned to driving or typing. You can read more in is hand arthritis embolization painful? and the recovery timeline.

Risks and side effects

None of the five hand studies reported a major or severe adverse event, and none reported a case of finger tissue damage or lasting numbness. Two limits on that statement are important.

First, the three largest studies are available to us only as summaries that do not list minor side effects. The one study with full detail, the 9-patient pilot, reported that the treated hand turned pale in all 9 patients and returned to its normal color about 30 minutes later. Four of the 9 had a temporary spasm of the wrist artery that left no lasting problem.

Second, about 200 patients is far too few to rule out rare, serious problems. The concern researchers name is reduced blood flow to tissue that was not the target. The 2026 independent review states that joint-specific vascular safety is "not fully defined."

A study outside hand arthritis adds context. In a 2026 Korean report of 12 catheter-based embolization procedures for chronic wrist pain, done with a different agent, temporary net-like skin redness followed 7 of 12 procedures and cleared within a week. There was also one bulge at the artery puncture site and one tear in an arm artery. Both resolved.

The hand studies chose a short-acting agent for a reason. In a laboratory study, imipenem/cilastatin particles dissolved completely in about 92 minutes. The four studies that name their agent all used imipenem/cilastatin, a short-acting agent. The one U.S. study does not name its agent in its summary. The studies do not list warning signs to watch for at home, so ask at your visit which symptoms should prompt a same-day call. Our article on risks and side effects goes further.

Off-label status and insurance

Imipenem/cilastatin is approved by the FDA as an intravenous antibiotic for serious bacterial infections. Its label does not include embolization, so using it this way is off-label. No embolic agent is approved or cleared by the FDA specifically for hand or finger arthritis.

On insurance, the payer policies we reviewed address the knee and classify it as experimental, investigational or not medically necessary. Aetna's embolization policy lists knee embolization for arthritis among unproven procedures. The Cigna (eviCore) guideline and the Carelon guideline used by Anthem plans both treat embolization uses they do not specifically list as not medically necessary. We found no policy written about hand or finger embolization. Since the hand has less evidence than the knee, expect your plan to review it as investigational. Check with your plan. Our office verifies benefits before treatment. More detail is in is hand arthritis embolization covered by insurance?

Your consultation in Manhattan

A consultation is mainly about two questions: is osteoarthritis really the source of your pain, and have the standard treatments had a fair trial? A consultation typically includes a review of your history and what you have already tried, an exam of your hands and the circulation at your wrists, and a look at your X-rays. In one study, doctors also checked that the hand had good backup circulation before using the wrist artery.

Dr. Fox will tell you plainly whether embolization is reasonable to consider or whether a hand therapist, a rheumatologist or a hand surgeon is the better next step.

Fox Vein & Vascular is at 1041 Third Avenue in Manhattan. Come with realistic expectations: an early-stage treatment with encouraging but unproven results, a possible second session, and no promises about outcome.

Frequently Asked Questions

Is hand arthritis embolization a proven treatment?

No. It is supported by five small uncontrolled case series with 204 patients in total, and no randomized or sham-controlled trial has been published. The American and European hand osteoarthritis guidelines do not mention it, and a 2026 independent review called the evidence hypothesis-generating.

Will I need more than one session?

Possibly. The largest study (92 patients) planned two procedures one to two months apart, and a 9-patient study gave every patient two sessions. In that small study, pain partly returned at one month in 4 of 9 patients.

Does embolization fix the arthritis itself?

No. It does not rebuild cartilage or change the shape of the joint, and no study has measured any effect on joint damage. The studies measured pain and, with mixed results, hand function.

What is injected during the procedure?

Nearly all published hand studies used imipenem/cilastatin, an antibiotic that forms tiny short-lived particles and is used off-label for this purpose. The one U.S. study did not name its agent in the published summary. Ask Dr. Fox what he uses and why.

Can it be done if I have rheumatoid arthritis or Raynaud's?

The published studies enrolled people with osteoarthritis only, and research protocols excluded rheumatoid arthritis and Raynaud's syndrome. There is no published information on how patients with those conditions do.

Keep Reading

Sources

Medically reviewed by David Fox, MD, FACS, RPVI. This article is general information, not a substitute for a medical evaluation.

Living with joint or tendon pain that hasn’t improved? Schedule a consultation with Dr. David Fox at Fox Vein & Vascular in Manhattan to find out whether embolization is right for you. Call (212) 362-3470 or request an appointment online.